Scribe Therapeutics (SCTX) Stock Forecast: StockMap's 2-Week Call

SCTX stock forecast: StockMap's model calls Scribe Therapeutics Strong Underperform for the two weeks after the Nov 18 close: it expects SCTX to trail the growth index. It is a call on the gap, not a price target. Right in 4 of 6 two-week windows on SCTX since Aug 26; by chance, a call on the same dates was right 61% of the time.

Scribe Therapeutics last closed at $14.05, -10.91% on the session.

Against the IVW growth benchmark the position is -10.93% over the forecast window.

Scribe Therapeutics' market cap is $259.32M as of November 18, 2026.

Calls down ↘: the model's call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -75 (behind).

Where SCTX sits: sized by market cap, coloured by the day's move.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

38 daily calls for SCTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

Scribe Therapeutics is classified under Health Care / Biotechnology.

StockMap tracks Scribe Therapeutics as the 218th largest of the 393 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 195 Moderate Underperform, 141 Neutral, 42 Strong Underperform and 15 Moderate Outperform.

On that composite Scribe Therapeutics ranks 388th of 393 in the group, against a group median of -0.27.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 18, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Scribe Therapeutics (SCTX) — StockMap 2-week forecast & tracked accuracy